Market Overview

Markets are under pressure from escalating Middle East tensions after US attacks on Iran, with the S&P 500 dropping 1.62% yesterday and futures struggling to recover. Energy stocks are the clear outperformers (IYE +27% YTD), while chipmakers and AI names are selling off on geopolitical risk repricing. A rotation into defensive sectors and LatAm/energy names is evident in today’s top movers list.

Claude’s Call

FLAT — After yesterday’s sharp sell-off on Iran escalation, I expect a choppy consolidation day as the market digests conflicting forces: geopolitical fear (bearish) vs. a dip-buying reflex in oversold tech (bullish). The Trump threat headlines will keep a lid on any sustained rally, and with Oracle plunging post-earnings, sentiment in mega-cap tech stays fragile.

Top Movers

ELVN (+18.07%) — $44.56 → $52.00 (+16.7% upside) Thesis: This is a legitimate clinical catalyst move — FDA alignment on dose recommendation for a late-stage CML trial reported today, plus ENABLE trial data being presented at EHA Congress. Biotech binary events like this can sustain multi-day momentum when the news is genuinely de-risking. RSI at 50 suggests this isn’t technically overbought yet despite the move, meaning there’s room before exhaustion sets in. Levels: Exit at $52 (prior 6-month high area). Support at $37.50 (pre-gap level).

CRDO (+10.49%) — $257.45 → $280.00 (+8.8% upside) Thesis: Post-earnings momentum continues after FQ4 2026 beat — Mizuho raised PT to $260+ and the Dust Photonics acquisition positions the company for optical AI infrastructure demand in FY2027. Revenue tripled YoY, and rising estimates signal continued institutional re-rating. This is one of the strongest fundamental AI stories outside of NVDA, but at $257 the stock is expensive on an absolute basis. Levels: Exit at $280 (Mizuho’s revised PT area). Support at $222 (24/7 Wall St. fair value estimate, also pre-earnings consolidation zone).

AMC (+8.98%) — $2.24 → $2.50 (+11.6% upside) Thesis: Blockbuster May attendance data and the strongest theater year since 2019 are real tailwinds, but this is still a highly leveraged, cash-burning business trading on sentiment and short-squeeze mechanics. RSI at 68.7 is approaching overbought territory. The “summer blockbuster thesis” has a shelf life of 6-8 weeks — this is a trade, not an investment. Levels: Exit at $2.50 (round number resistance). Support at $1.95 (week-ago levels).

MAAS (+8.98%) — $11.96 → $13.50 (+12.9% upside) Thesis: This AI full-stack company surged 84% in April on AI positioning and continues riding the theme, but today’s move comes with RSI at 25.58 — deeply oversold bouncing off lows. The contrarian setup is interesting: a beaten-down AI play catching a bid while mega-cap AI sells off on geopolitical risk. Thin coverage and ADR status add risk. Levels: Exit at $13.50 (50% retracement of recent decline). Support at $9.56 (prior consolidation base from May).

PRI (+6.67%) — $280.64 → $300.00 (+6.9% upside) Thesis: Primerica delivered 13% growth in adjusted net operating income in Q1, and the life insurance sector benefits from the current rate environment. Zacks highlighted it alongside RGA and VOYA as sector winners. This is a boring-but-works story — steady compounding in a sector rotation that favors financials when yields stay elevated. Levels: Exit at $300 (psychological round number, near prior highs). Support at $265 (10.63% trailing 90-day gain base).

OSCR (+4.62%) — $27.57 → $32.00 (+16.1% upside) Thesis: Barclays upgrade to overweight with an AI-in-healthcare angle gives this institutional sponsorship at a key inflection point. Stock hit 52-week highs two days in a row — this is a breakout, not just a bounce. RSI at 70.3 is elevated but breakouts often run into the 75-80 range before cooling. The “AI changes health insurance” narrative has legs given Oscar’s tech-first model. Levels: Exit at $32 (next round number / extension target). Support at $23.60 (pre-upgrade gap-fill level).

CHEF (+4.73%) — $87.75 → $95.00 (+8.3% upside) Thesis: Upgraded to Zacks #1 Strong Buy with RSI at 16.96 — this is a textbook oversold bounce with fundamental confirmation. EPS growth + cash flow generation justify the re-rating. Specialty food distribution is defensive and benefits from restaurant/hospitality reopening trends. The 16.79% 30-day return suggests the bounce is already underway and accelerating. Levels: Exit at $95 (prior 3-month high area). Support at $76.46 (recent consolidation low).

TEO (+6.15%) — $15.10 → $17.00 (+12.6% upside) Thesis: Argentine telecom riding the broader LatAm/Argentina investment theme (CEPU also up 5%+ today). Zacks momentum pick with RSI at 19.72 — absurdly oversold, suggesting this bounce has significant room. Multiple analyst services flagging it as undervalued with strong momentum, which is a rare combination. Levels: Exit at $17.00 (30.5% analyst upside target aligns with ~$20 consensus). Support at $13.00 (prior month low).

Headlines to Watch

  • US attacks on Iran escalate Middle East tensions — Defense and energy names benefit; growth/tech faces multiple compression as risk premiums rise. Position accordingly.
  • Oracle plunges on earnings — WSB’s top ticker (371 mentions, 80% bullish) is about to get a reality check; watch for contagion into enterprise software names.
  • Energy ETF IYE up 27% YTD — Sector rotation into energy is a crowded trade now; late entries carry reversal risk if Iran tensions de-escalate.
  • Investors ditching Magnificent 7 for “MANGOS” — The rotation away from mega-cap concentration into new AI beneficiaries (like CRDO, MAAS) is a real structural shift, not just headline fodder.
  • Vanguard S&P 500 ETF hits $1 trillion in assets — Passive inflows continue to dominate, meaning market-cap-weighted concentration risk persists despite the “diversify” narrative.
  • Trump threatening new tariffs/Iran action — Geopolitical headline risk keeps VIX elevated; defensive positioning warranted for swing traders.

Claude’s Top Picks

CHEF (+4.73% today, +13.17% week) — $87.75 → $95.00 (+8.3% upside) Valuation: Zacks highlights projected EPS growth and cash flow self-sufficiency — trading at a bargain relative to food distribution peers given 22.55% YTD gains vs. sector median of ~12%. Upside: RSI at 16.96 is extreme oversold reading bouncing with a Zacks #1 Strong Buy upgrade — mean reversion alone suggests $95+. Risk: Specialty foodservice is tied to restaurant spending, which could soften if consumer discretionary weakens further on geopolitical uncertainty.

TEO (+6.15% today, +14.17% week) — $15.10 → $17.00 (+12.6% upside) Valuation: Trades well below analyst consensus target (~$20+), flagged as attractively priced despite strong momentum — rare value + momentum combo. Upside: RSI at 19.72 with Argentina macro reform tailwinds and multiple Zacks momentum/value screen appearances suggest significant re-rating ahead. Risk: Argentine peso volatility and ADR liquidity risk; EM telecom names can gap down violently on macro shocks.

ELVN (+18.07% today, +25.56% week) — $44.56 → $52.00 (+16.7% upside) Valuation: Clinical-stage biotech, so EV/Revenue doesn’t apply — valued on pipeline probability; FDA alignment de-risks the lead asset materially. Upside: EHA Congress presentation today could drive additional re-rating as hematology community digests data; CMO insider sale at higher levels suggests $44 isn’t the ceiling. Risk: Biotech binary risk — any safety signal in data could reverse the entire move; the CMO selling 5,000 shares recently is a minor yellow flag.

CRDO (+10.49% today, +18.37% week) — $257.45 → $280.00 (+8.8% upside) Valuation: Revenue tripled YoY with optical AI inflection in FY2027; at current multiples the PEG ratio is favorable given 100%+ revenue growth, though absolute P/E looks stretched. Upside: Dust Photonics acquisition + rising estimates + Mizuho PT raise create a “wall of analyst support” that institutions chase. Risk: At $257, any broad AI/chip sector selloff (like yesterday’s) could trigger a 10-15% pullback quickly; geopolitical risk to supply chains is elevated.

INNV (+6.21% today, +15.21% week) — $8.30 → $9.75 (+17.5% upside) Valuation: Trading below $10 despite raising FY2026 revenue guidance to $950-975M; market punished the wider loss but top-line trajectory is clearly improving. Upside: RSI at 8.11 is the most oversold reading on the entire board — this is a coiled spring if any positive catalyst hits; PACE model benefits from aging demographics secular trend. Risk: Net losses are widening even as revenue grows, raising cash burn concerns; stock dropped 9% after raising guidance, which signals skeptical institutional sentiment.

Avoid

AMC ($2.24, +8.98%) — RSI at 68.7 approaching overbought on a cash-burning business with no fundamental improvement. Summer blockbuster narrative is priced in; the last time AMC ran on attendance data it gave back gains within 2 weeks. This is a momentum trap for latecomers.

OSCR ($27.57, +4.62%) — While the Barclays upgrade is real, RSI at 70.3 after back-to-back 52-week highs means you’re chasing an already-extended breakout. Wait for a pullback to $24-25 for a better risk/reward entry rather than buying the gap.

MAAS ($11.96, +8.98%) — Thin ADR with limited analyst coverage, up 84% in one week in April and now bouncing erratically. The “AI full-stack” narrative is vague and unverifiable for a company with minimal English-language financial disclosure. Speculation, not investment.

WSB Sentiment Check

ORCL — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — Oracle is plunging post-earnings today per market headlines. This is classic WSB buying the narrative before earnings and getting crushed on the print. The 80% bullish reading right before a gap-down is peak contrarian signal — expect capitulation posts by end of day.

MU — WSB says: MIXED (55% bullish) Claude says: PARTIALLY AGREE — Micron benefits from AI memory demand structurally, but with chipmakers selling off on geopolitical risk yesterday (-1.98% on QQQ), the mixed read is appropriate. Wait for $85-90 support test before getting constructive.

NVDA — WSB says: MIXED (55% bullish) Claude says: AGREE — The mixed sentiment actually reflects reality for once. NVDA is facing multiple headwinds (geopolitical supply chain risk, China restrictions, rotation into “next gen” AI plays like CRDO). The days of unanimous NVDA bullishness are over; this is now a show-me stock.

MSFT — WSB says: BEARISH (30% bullish) Claude says: DISAGREE — WSB being bearish on MSFT at 30% bullish is often a buy signal. Microsoft’s Azure/AI positioning and capital returns make this a defensive mega-cap in selloffs. The crowd usually gets bearish on quality names right before they bounce.

SPCX — WSB says: MIXED (55% bullish) Claude says: NEUTRAL — This is a SPAC ETF, not a single company thesis. WSB’s interest likely reflects pre-deal speculation in underlying SPACs. Low conviction play with no clear technical or fundamental edge.